Veteran Life Sciences Executive Richard W. Pascoe Appointed as Chief Executive Officer Bringing Extensive Strategic Leadership and Portfolio Building Expertise to Foci Healthcare
MANHASSET, NY / ACCESSWIRE / September 9, 2024 / Foci Healthcare today announced the appointment of Richard W. Pascoe as Chief Executive Officer. He brings more than 30 years of leadership experience with development- and commercial-stage biopharma companies and the proven ability to guide businesses through value-driven transformations. The Company also announced the resignation of Anthony Amato as Chief Executive Officer effective immediately.
In his role, Pascoe will lead Foci’s efforts to grow the Company’s current branded product revenues as well as broaden the Company’s portfolio by identifying complementary branded pharmaceutical assets for in-licensing or purchase.
“We are excited to welcome Richard as the incoming CEO during this pivotal time for Foci Healthcare”, Tom Allison, Managing Board Member,said. “He is a highly experienced industry leader whose combination of leadership skills and operating experience will enable the Company to achieve long-term success. On behalf of the Board, I also want to thank Tony for his service to the company and we wish him well in his future endeavors.”
Pascoe added, “I am honored for the opportunity to lead Foci Healthcare at this critical point in its evolution. I am committed to driving increased value with our existing branded products while, at the same time, evaluating opportunities to expand and strengthen our product portfolio. We have the ability to transform Foci into a growth oriented, multi-asset branded pharmaceutical company with the overarching goal of building a business that brings the greatest value to patients, healthcare professionals and our investors.”
Prior to joining Foci Healthcare, Pascoe was the CEO of several emerging biopharmaceutical companies, including Zevra Therapeutics and Histogen where he led their strategic transformation efforts. He also served as CEO of Somaxon Pharmaceuticals, where he spearheaded the Company’s growth and then its acquisition by Pernix, and CEO of Apricus Biosciences, where he led the sale of ex-US rights to its lead asset prior to completing a successful merger with Seelos Therapeutics. He currently serves on the board of directors of Seelos Therapeutics, Prizm Therapeutics and the Johnny Mac Soldiers Fund.
Over the course of his career, he has closed more than $2 billion in business development transactions and guided the launch of prescription therapeutics in multiple categories generating net U.S. sales of more than $1 billion. Pascoe is a graduate of the United States Military Academy at West Point and a decorated U.S. Army veteran earning the Bronze Star Medal during the Operation Desert Storm.
About Foci Healthcare.
Foci Healthcare, the parent company of Virtus Pharmaceuticals and Acertis Pharmaceuticals, is a privately held U.S.-based company committed to creating a healthier future for its customers, partners, and patients. Through innovative development and manufacturing collaborations, Foci Healthcare excels in delivering high-quality, safe, and valuable generic and branded prescription pharmaceuticals. Serving wholesalers, drug chains, and specialty pharmacies across multiple therapeutic categories, Foci Healthcare is dedicated to setting the highest standards in the industry.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Foci’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.
Investor and Media Contact Information:
Richard Pascoe
Email: Rpascoe@focihc.com
SOURCE: Foci Healthcare
